dc.creatorPolanía, Diana
dc.creatorGarcía Linares, Jorge
dc.creatorGarcía Linares, Carlos
dc.creatorRuiz, Pilar Cristina
dc.creatorMejía Rivera, Olga Mercedes
dc.date2011-11-30
dc.identifierhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/1281
dc.identifier10.18359/rmed.1281
dc.descriptionLos adenomas son los tumores corticoadrenales más comunes, con una prevalencia del 4%, siendo los carcinomas corticoadrenales raros, con una incidencia de 1 caso por millón de habitantes. La mitad de estos carcinomas son funcionales con diagnósticos más tempranos por los síndromes de exceso de hormonas que producen, a diferencia del restante 50% que es silente, con hallazgo de metástasis al momento del diagnostico en más de la mitad de ellos. Pueden tener una presentación esporádica o hacer parte de síndromes de cáncer familiar con anormalidades en genes que resultan en un imbalance entre oncogenes y genes supresores de tumor; además de constituirse como potenciales marcadores diagnósticos, pronósticos y terapéuticos de esta enfermedad. Ante la sospecha de carcinoma de corteza suprarrenal, deben tenerse en cuenta criterios clínicos, bioquímicos y radiológicos para establecer adecuadamente el diagnóstico, el cual debe confirmarse por histología.
dc.formatapplication/pdf
dc.languagespa
dc.publisherUniversidad Militar Nueva Granada
dc.relationhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/1281/1018
dc.relation/*ref*/Fassnacht, M., Libé, R., Kroiss, M., Allolio, B. Nat. Rev. Endocrinol. 7, 323–335 (2011).
dc.relation/*ref*/Pabon, N., Gomez, C., Garavito, G., Jimenez, C. Rev Colomb Cancerol 2005;9(3):123-129.
dc.relation/*ref*/Universität Würzburg Offizielle Homepage des Deutsche Nebennierenkarzinom-Registers [online], http://www.nebennierenkarzinom. de/ (2010).
dc.relation/*ref*/Libe, R., Bertherat, J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases.Eur J Endocrinol 2005;153:477-87.
dc.relation/*ref*/Geller, J., Mertens, R., Weiss, L. Adrenocortical carcinoma many questions remain unanswered. The Endocrinologist 2005;15:3009-312.
dc.relation/*ref*/Ribeiro, R., Pinto, E., Zambetti, G. Familial predisposition to adrenocortical tumors: Clinical and biological features and management strategies. Best Practice & Research Clinical Endocrinology & Metabolism 24 (2010) 477e490.
dc.relation/*ref*/Tissier, F., Cavard, C., Groussin, L et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Research 2005; 65: 7622e7627.
dc.relation/*ref*/Bisgaard, M., Fenger, K., Bulow S et al. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Human Mutation 1994; 3: 121e125.
dc.relation/*ref*/DeChiara, T., Robertson EJ & Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64: 849e859.
dc.relation/*ref*/Lapunzina, B., del Campo, C., Delicado, N.et al. Clinical guide to the management of patients with BeckwitheWiedemann syndrome. Anales de Pediatria (Barcelona) 2006; 64: 252e259.
dc.relation/*ref*/Teh SH & Ong GB. Early presentation of right adrenal mass, hepatoblastoma and hepatic cavernous haemangioma in BeckwitheWiedemann Syndrome. The Medical Journal of Malaysia 2007; 62: 345e346.
dc.relation/*ref*/Schimmer, B. & White, P. Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Mol. Endocrinol. 24, 1322–1337 (2010).
dc.relation/*ref*/Sbiera, S. et al. High diagnostic and prognostic value of steroidogenic factor‑1 expression in adrenal tumors. J. Clin. Endocrinol. Metab. 95, E161–E171 (2010).
dc.relation/*ref*/Bernini, G. et al. Angiogenesis in human normal and pathologic adrenal cortex. J. Clin. Endocrinol. Metab. 87, 4961–4965 (2002).
dc.relation/*ref*/Isobe, M., Bravo, E., Givol, D et al. Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986; 320: 84e85.
dc.relation/*ref*/Bertherat, J., Gimenez, R. New insights in the genetics of adrenocortical tumours, pheochromocytomas and paragangliomas. Horm Metab Res 2005;37:384-90.
dc.relation/*ref*/Sidhu, S., Gicquel, C., Bambach C et al. Clinical and molecular aspects of adrenocortical tumourigenesis. ANZ J Surg 2003;73:727-38.
dc.relation/*ref*/Zambetti, G. The p53 mutation “gradient effect” and its clinical implications. Journal of Cellular Physiology 2007; 213: 370e373.
dc.relation/*ref*/Gonzalez, K., Noltner, K., Buzin, C et al. Beyond LieFraumeni Syndrome: clinical characteristics of families with p53 germline mutations. Journal of Clinical Oncology 2009; 27: 1250e1256.
dc.relation/*ref*/Beuschlein, F., Fassnacht, M., Klink, A., Allolio, B. & Reincke, M. ACTH-receptor expression, regulation and role in adrenocortial tumor formation. Eur. J. Endocrinol. 144, 199–206 (2001).
dc.relation/*ref*/Stewart, P. M., Walker, B. R., Holder, G., O’Halloran, D. & Shackleton, C. H. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing’s syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J. Clin. Endocrinol. Metab. 80, 3617–3620 (1995).
dc.relation/*ref*/Universität Würzburg Offizielle Homepage des Deutsche Nebennierenkarzinom-Registers [online], http://www.nebennierenkarzinom. de/ (2010).
dc.relation/*ref*/Hyodo, T., Megyesi, K., Kahn, C. R., McLean, J. P. & Friesen, H. G. Adrenocortical carcinoma and hypoglycemia: evidence for production of nonsuppressible insulin-like activity by the tumor. J. Clin. Endocrinol. Metab. 44, 1175–1184 (1977).
dc.relation/*ref*/Francois C, Rangachari B, Bova D. Case report: mammography and sonography of pathologically proven adrenal cortical carcinoma metastasic to the breast. Am J Roentgenol 2005;184:1279-81.
dc.relation/*ref*/European Network for the Study of Adrenal Tumours Adrenocortical carcinomas [online], http://www.ensat.org/acc. htm (2010).
dc.relation/*ref*/Fassnacht, M. & Allolio, B. Clinical management of adrenocortical carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 23, 273–289 (2009).
dc.relation/*ref*/Schteingart, D., Doherty, G., Gauger, P. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine Related Cancer 2005;12:667-80.
dc.relation/*ref*/Ilias, I., Sahdev, A., Reznek, R. H., Grossman, A. B. & Pacak, K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr. Relat. Cancer 14, 587–599 (2007).
dc.relation/*ref*/Groussin, L. et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J. Clin. Endocrinol. Metab. 94, 1713–1722 (2009).
dc.relation/*ref*/Hahner, S. et al. [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome.
dc.relation/*ref*/Hennings, J. et al. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J. Clin. Endocrinol. Metab. 91, 1410–1414 (2006)
dc.relation/*ref*/Sasano, H. et al. Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Hum. Pathol. 26, 1154–1156 (1995).
dc.relation/*ref*/Aiba M, Fujibayashi M. Histopathological diagnosis and prognostic factors in adrenocortical carcinoma. Endocr Pathol 2005;16:13-22.
dc.relation/*ref*/Quayle, F. J. et al. Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery 142, 497–502 (2007).
dc.relation/*ref*/Murphy, M. M. et al. Trends in adrenalectomy: a recent national review. Surg. Endosc. 24, 2518–2526 (2010).
dc.relation/*ref*/Porpiglia, F. et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur. Urol. 57, 873–878 (2010).
dc.relation/*ref*/Brix, D. et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur. Urol. 58, 609–615 (2010).
dc.relation/*ref*/Terzolo, M. et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 356, 2372–2380 (2007).
dc.relation/*ref*/Huang, H. & Fojo, T. Adjuvant mitotane for adrenocortical cancer—a recurring controversy. J. Clin. Endocrinol. Metab. 93, 3730–3732 (2008).
dc.relation/*ref*/Terzolo, M., Fassnacht, M., Ciccone, G., Allolio, B. & Berruti, A. Adjuvant mitotane for adrenocortical cancer- -working through uncertainty. J. Clin. Endocrinol. Metab. 94, 1879–1880 (2009).
dc.relation/*ref*/Fassnacht, M. et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J. Clin. Endocrinol. Metab. 95, 4925–4932 (2010).
dc.relation/*ref*/Terzolo, M., Fassnacht, M., Ciccone, G., Baudin, E., Haak, H., Berruti, A. Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence. 2008-2014
dc.relation/*ref*/US National Institutes of Health Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00777244 (2010).
dc.relation/*ref*/Daffara, F. et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr. Relat. Cancer 15, 1043–1053 (2008).
dc.relation/*ref*/Polat, B. et al. Radiotherapy in adrenocortical carcinoma. Cancer 115, 2816–2823 (2009).
dc.relation/*ref*/Sabolch, A. et al. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. doi:10.1016/j.ijrobp.2010.04.030.
dc.relation/*ref*/Erdogan, I. et al. Impact of surgery on clinical outcome in patients with recurrence of adrenocortical carcinoma. Endocrine Abstracts (10th European Congress of Endocrinology), 20, P194 (2009).
dc.relation/*ref*/Khan, T. S. et al. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann. Oncol. 11, 1281–1287 (2000).
dc.relation/*ref*/Berruti, A. et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr. Relat. Cancer 12, 657–666 (2005).
dc.relation/*ref*/Sperone, P. et al. Gemcitabine plus metronomic 5‑fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr. Relat. Cancer 17, 445–453 (2010).
dc.relation/*ref*/Castinetti, F. et al. Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur. J. Endocrinol. 160, 1003–1010 (2009).
dc.relation/*ref*/Johanssen, S. & Allolio, B. Mifepristone (RU 486) in Cushing’s syndrome. Eur. J. Endocrinol. 157, 561–569 (2007).
dc.relation/*ref*/Carden, C. P. et al. Phase I study of intermittent dosing of OSI‑906, a dual tyrosine kinase inhibitor of insulin-like growth factor‑1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J. Clin. Oncol. 28 (Suppl.), abstr 2530 (2010).
dc.relation/*ref*/Bauditz, J., Quinkler, M. & Wermke, W. Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer—a case report and review of the literature. Exp. Clin. Endocrinol. Diabetes 117, 316–319 (2009).
dc.relation/*ref*/Bilimoria, K. Y. et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113, 3130–3136 (2008).
dc.rightsDerechos de autor 2015 Revista Med
dc.sourceRevista Med; Vol. 19 No. 2 (2011): july - december; 207-216
dc.sourceRevista Med; Vol. 19 Núm. 2 (2011): julio - diciembre; 207-216
dc.source1909-7700
dc.source0121-5256
dc.subjectcarcinoma
dc.subjectfisiopatología
dc.subjectalteraciones genéticas
dc.subjectestadiaje
dc.subjectterapia
dc.subjectseguimiento
dc.titleCarcinoma corticoadrenal. Revisión de tema
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución